Med. Pro Praxi 2008; 5(1): 23-27

Karcinom plic

prof. MUDr. Petr Zatloukal CSc
Klinika pneumologie a hrudní chirurgie, FN Na Bulovce, 3. LF UK Praha, IPVZ Praha

V České republice je karcinom plic nejčastější příčinou úmrtí na zhoubný novotvar. Většina nemocných má v době stanovení diagnózy příznaky. Vyšetření nemocných se zaměřuje na stanovení morfologického typu a rozsahu onemocnění. Hlavní léčebnou modalitou u malobuněčného karcinomu plic je chemoterapie, u nemalobuněčného typu operace. Onemocnění je obvykle diagnostikováno až v pokročilém stadiu a operační léčbu lze použít je u malé části nemocných. Většina nemocných je léčena chemoterapií, buď v kombinaci s jinými léčebnými modalitami, nebo u generalizovaného onemocnění karcinomu plic samotnou chemoterapií. V posledních letech se uplatňuje i biologická léčba. Celkové výsledky léčby karcinomu plic jsou neuspokojivé a jsou proto hledány nové léčebné strategie.

Keywords: bronchogenní karcinom, rakovina plic, léčba, nemalobuněčný karcinom plic, malobuněčný karcinom plic, biologická léčba

Published: March 27, 2008  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Zatloukal P. Karcinom plic. Med. praxi. 2008;5(1):23-27.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Arriagada R, Bergman B, Dunant A et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small cell lung cancer. N Engl J Med 2004; 350: 351-360. Go to original source... Go to PubMed...
    2. Bunn PA. To treat or not to treat non-small-ell lung cancer patients? Current perspectives. Oncology 1999; 13 (dopl. 4): 9-15. Go to PubMed...
    3. Depierre A, Milleron B, Moro-Sibilot D et al. Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II a IIIa non-small cell lung cancer. J Clin Oncol 2002; 20: 247-253. Go to original source...
    4. Fukuoka M, Furuse K, Saijo N et al. Randomized trial of Cyclophosphamide, Doxorubicin and Vincristine versus Cisplatin and Etoposide versus alternation of these regimens in small cell lung cancer. J. Natl. Cancer Inst 1991; 83: 855-861. Go to original source... Go to PubMed...
    5. Martini N, Kris MG, Flehinger BJ et al. Preoperative chemotherapy for stage IIIA (N2) lung cancer: Te Sloan Kettering expereince with 136 patients. Ann. Thorac. Surg. 1993; 35: 1365-1374. Go to original source... Go to PubMed...
    6. Martini N, Kris MG, Gralla RJ. The effect of pre-operative chemotherapy on the resectability of nonsmall-cell lung carcinoma with mediastinal node metastases. Ann. Thorac. Surg. 1988; 45: 370-379. Go to original source... Go to PubMed...
    7. Mountain CF. Revisions in the international system for staging lung cancer. Chest 1997; 111: 1710-1717. Go to original source... Go to PubMed...
    8. Murray N, Turrisi AT. A review of first-line treatment for small-cell lung cancer. J Thorac Oncol 2006; 1: 270-278. Go to original source... Go to PubMed...
    9. NCCN Clinical Practice Guidelines in Oncology: Small cell lung cancer. NCCN National Comprehensive Cancer Network, verze 1. 2008, 2007, www.nccn.org, 24-25.
    10. Pass HI, Pogrebniak HW, Steinberg SM et al. Randomized trial of neoadjuvant herapy for lung cancer: Interim analysis. Ann. Thorac. Surg. 1992; 53: 992-998. Go to original source... Go to PubMed...
    11. Reck M, von Pawel J, Zatloukal P et al. BO 17704: a phase III study of first-line cisplatin and gemcitabine with bevacizumab or placeboin patients with advanced or recurrent nonsquamous non-small cell lung cancer (NSCLC). J. Thorac. Oncol. 2007; 2 (Suppl 8): S360-S361. Go to original source...
    12. Rosell R, Gomez-Godina J, Comps J. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small cell lung cancer. N. Engl. J. Med. 1994; 330: 153-158. Go to original source... Go to PubMed...
    13. Roth BJ, Johnson DH, Einhorn LH et al. Randomized study of Cyclophosphamide, Doxorubicin and Vincristine versus Etoposide and Cisplatin versus alternation of these two regimens in extensive small cell lung cancer: A phase III trial of the Southeastern Cancer Study Group. J. Clin. Oncol. 1992; 10: 282-291. Go to original source... Go to PubMed...
    14. Roth JA, Fossella F, Komaki R et al. A andomized trial comparing preoperative chemotherapy and surgery with surgery alone in resectable non-small-cell-lung cancer. J. Natl. Canc. Inst. 1994; 86: 673-680. Go to original source... Go to PubMed...
    15. Sandler A, Gray R, Perry MC et al. Paclitaxel-carboplatin alone or with bevacizumab for nonsmall-cell lung cancer. N Engl J Med 2006; 355: 2542-2550. Go to original source... Go to PubMed...
    16. Stahel RA, Ginsberg R, Havemann K et al. Staging and prognostic factors in small cell lung cancer: a consensus report. In: Hansen HH, Kristjansen PEG (eds.). Management of small cell lung cancer. Third IASLC Workshop on small cell lung cancer. Elsevier Amsterdam 1989: 1-8.
    17. Travis WD, Colby TV, Corrin B, Shimosato Y, Brambilla E. Histological typing of lung and pleural tumors. International histological classification of tumors. World Health Organisation, Third Edition, Springer, Berlin, Germany, 1999. Go to original source...
    18. ÚZIS. Novotvary 2004 ČR. Zdravotnická statistika, ÚZIS, Praha 2007.
    19. Zelen M. Keynote address on biostatistics and data retrival. Cancer Chemother. Rep. 1973; 4(3): 31-42.

    Return to the content


    Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.